A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity
Latest Information Update: 05 Oct 2024
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms SURMOUNT-MMO
- Sponsors Eli Lilly and Company
- 15 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2022 Status changed from not yet recruiting to recruiting.
- 30 Sep 2022 New source identified and integrated ClinicalTrials.gov: US National Institutes of Health